SEC Comment Letter 0000000000-24-000128 to PRECIGEN, INC. (PGEN)
PRECIGEN, INC.
Date: Jan. 4, 2024 · CIK: 0001356090 · Accession: 0000000000-24-000128
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276337
Letter
United States securities and exchange commission logo January 4, 2024 Helen Sabzevari President and Chief Executive Officer Precigen, Inc. 20374 Seneca Meadows Parkway Germantown, Maryland 20876 Re:Precigen, Inc. Registration Statement on Form S-3 Filed December 29, 2023 File No. 333-276337 Dear Helen Sabzevari: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Yasin Keshvargar, Esq.
Show Raw Text
United States securities and exchange commission logo
January 4, 2024
Helen Sabzevari
President and Chief Executive Officer
Precigen, Inc.
20374 Seneca Meadows Parkway
Germantown, Maryland 20876
Re:Precigen, Inc.
Registration Statement on Form S-3
Filed December 29, 2023
File No. 333-276337
Dear Helen Sabzevari:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Yasin Keshvargar, Esq.